We claim:

1 (currently amended). A compounds of formula I



I

wherein

R8, R9, R10, R11 are each independently H, F, Cl, Br, OH, NO_2, CN, O-(C_1-C_6)alkyl, O-(C_2-C_6)alkenyl, O-(C_2-C_6)alkynyl, O-SO_2-(C_1-C_4)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl or (C_2-C_6)alkynyl,

wherein said O-(C_1-C_6)alkyl, O-(C_2-C_6)alkenyl, O-(C_2-C_6)alkynyl, O-SO_2-(C_1-C_4)-alkyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl and (C_2-C_6)alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

R1, R2 are each independently H, (C_1-C_6)-alkyl,

wherein said (C_1-C_6)-alkyl radical is optionally substituted by OH, O-(C_1-C_4)-alkyl, NH_2, NH(C_1-C_4)-alkyl, N[(C_1-C_6)-alkyl]$_2$, O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, (C_1-C_6)-alkylene-COOH or (C_1-C_6)-alkylene-COO-(C_1-C_6)-alkyl;

R3, R4, R5, R6 are each independently H, F, Cl, Br, NO_2, CN, O-R12, O-phenyl, S-R12, COOR12, N(R13)(R14), (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene or O-(C_1-C_5)-alkyl-COOR12,

wherein said (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene and O-(C_1-C_5)-alkyl-COOR12 radicals are optionally mono- or polysubstituted by F, Cl, Br, OR12, COOR12 or N(R13)(R14);

R7 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylcarboxy-(C_1-C_6)-alkylene, COOR12, (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene, heterocyclic radical, heteroaryl, heteroaryl-(C_1-C_4)-alkylene or heteroarylcarbonyl,

wherein the alkyl, cycloalkyl, alkylene, alkenyl and alkynyl groups contained in said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylcarboxy-(C_1-C_6)-alkylene, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene and

heteroaryl-(C_1-C_4)-alkylene radicals are optionally mono- or polysubstituted by F, Cl, Br, OR12, COOR12, $CONH_2$, CONH(C_1-C_6)-alkyl, CON[(C_1-C_6)-alkyl]$_2$ or N(R13)(R14), and wherein the aryl and heteroaryl groups contained in said (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene, heteroaryl, heteroaryl-(C_1-C_4)-alkylene and heteroarylcarbonyl radicals are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-R12, S-R12, COOR12, N(R13)(R14) or (C_1-C_6)-alkyl;

R12 is H, (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl or (C_2-C_8)-alkynyl, wherein said (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl and (C_2-C_8)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl, Br, OH or O-(C_1-C_4)-alkyl,

R13, R14 are each independently H, (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, COO-(C_1-C_4)-alkyl, COO-(C_2-C_4)-alkenyl, phenyl or SO_2-phenyl,

wherein said phenyl and SO_2-phenyl radicals are optionally mono- or disubstituted by F, Cl, CN, OH, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, CF_3, OCF_3, COOH, COO(C_1-C_6)-alkyl or $CONH_2$; or

R13 and R14, taken together with the nitrogen atom to which they are attached, form a 3-7 membered, saturated, heterocyclic ring which may contain up to 2 further heteroatoms from the group of N, O and S, and wherein said heterocyclic ring is optionally mono-, di- or trisubstituted by F, Cl, Br, OH, oxo, N(R21)(R22) or (C_1-C_4)-alkyl; and

R21, R22 are each independently H, (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, COO-(C_1-C_4)-alkyl, COO-(C_2-C_4)-alkenyl, phenyl or SO_2-phenyl,

wherein said phenyl and SO_2-phenyl radicals are optionally mono- or disubstituted by F, Cl, CN, OH, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, CF_3, OCF_3, COOH, COO(C_1-C_6)-alkyl or $CONH_2$;

with the proviso that when R5 is halogen or unsubstituted (C_1-C_6)-alkyl, R7 cannot be heterocyclic radical or heteroaryl;

with the proviso that when R8, R9, R10 and R11 are F, and R1 and R2 are H, and R3, R4, R5 and R6 are H, then R7 cannot be (C_1-C_6)-alkyl wherein the alkyl group is mono-substituted by COOR12 wherein R12 is H;

and pharmaceutically acceptable salts thereof.

2 (original). The compound of Claim 1 wherein

R8, R9, R10, R11 are each independently H, F, Cl, Br, OH, NO_2, CN or O-(C_1-C_6)-alkyl, wherein said O-(C_1-C_6)-alkyl radical is optionally mono- or polysubstituted by F, Cl or Br;

R1, R2 are each H;

R3, R4, R5, R6 are each independently, H, F, Cl, Br, NO_2, CN, O-R12, O-phenyl, S-R12, COOR12, N(R13)(R14), (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene or O-(C_1-C_5)-alkyl-COOR12,

wherein said (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene and O-(C_1-C_5)-alkyl-COOR12 radicals are optionally mono- or polysubstituted by F, Cl, Br, OR12, COOR12 or N(R13)(R14);

R7 is H, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylcarboxy-(C_1-C_6)-alkylene, COOR12, (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene, heteroaryl, heteroaryl-(C_1-C_4)-alkylene or heteroarylcarbonyl,

wherein the alkyl, cycloalkyl, alkylene, alkenyl and alkynyl groups contained in said (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_6)-alkylcarboxy-(C_1-C_6)-alkylene, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene and heteroaryl-(C_1-C_4)-alkylene radicals are optionally mono- or polysubstituted by F, Cl, Br, OR12, COOR12, $CONH_2$, CONH(C_1-C_6)-alkyl, CON[(C_1-C_6)-alkyl]$_2$ or N(R13)(R14), and wherein the aryl and heteroaryl groups contained in said (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkylene, heteroaryl, heteroaryl-(C_1-C_4)-alkylene and heteroarylcarbonyl radicals are optionally mono- or polysubstituted by F, Cl, Br, NO_2, CN, O-R12, S-R12, COOR12, N(R13)(R14) or (C_1-C_6)-alkyl;

R12 is H, (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl or (C_2-C_8)-alkynyl,

wherein said (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl and (C_2-C_8)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl, Br, OH or O-(C_1-C_4)-alkyl;

R13, R14 are each independently H, (C_1-C_8)-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkylene, COO-(C_1-C_4)-alkyl, COO-(C_2-C_4)-alkenyl, phenyl or SO_2-phenyl,

wherein said phenyl and SO_2-phenyl radicals are optionally mono- or disubstituted by F, Cl, CN, OH, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, CF_3, OCF_3, COOH, COO(C_1-C_6)-alkyl or $CONH_2$; or

R13 and R14, taken together with the nitrogen atom to which they are attached, form a 3-7 membered, saturated, heterocyclic ring which may

contain up to 2 further heteroatoms from the group of N, O and S, and wherein said heterocyclic ring is optionally mono-, di- or trisubstituted by F, Cl, Br, OH, oxo, N(R21)(R22) or (C_1-C_4)-alkyl; and

R21, R22 are each independently H or (C_1-C_8)-alkyl.

3 (original). The compound of Claim 2 wherein

R8, R9, R10, R11 are each independently H, F or Cl;

R1, R2, R4, R6 are each H;

R3, R5 are each independently H, Cl, OR12, COOR12, N(R13)(R14) or (C_1-C_6)-alkyl;

R7 is (C_1-C_6)-alkyl,

wherein said (C_1-C_6)-alkyl radical is optionally mono- or polysubstituted by F, OR12, COOR12 or N(R13)(R14),

(C_3-C_6)-cycloalkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_5)-alkylcarboxy-(C_1-C_6)-alkylene, COOR12, phenyl,

wherein said phenyl radical is optionally mono- or polysubstituted by F, OMe or OCF_3,

or benzyl,

wherein the phenyl ring of said benzyl radical is optionally substituted by OMe, pyridyl, thienyl, furanyl, indolylcarbonyl or benzofuranyl,

wherein said benzofuranyl radical is optionally substituted by Cl or OMe;

R12 is H or (C_1-C_8)-alkyl, wherein said (C_1-C_8)-alkyl radical is optionally mono- or polysubstituted by F;

R13, R14 are each independently H or (C_1-C_8)-alkyl; or

R13 and R14, taken together with the nitrogen atom to which they are attached, form a 5-membered, saturated heterocyclic ring.

4 (original). A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

5 (original). The pharmaceutical composition of Claim 4 further comprising one or more blood sugar-reducing active ingredients.

6 (original). The pharmaceutical composition of Claim 4 further comprising one or more statins.

7 (original). A method of treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

8 (original). A method for lowering blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

9 (original). A method of treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further blood sugar-reducing active ingredient.

10 (original). A method for lowering blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further blood sugar-reducing active ingredient.